Consolidated Statements of Earnings (unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net revenue:
Product revenue	$ 31,766,000	$ 27,926,000	$ 92,216,000	$ 81,197,000
License, royalty and collaboration revenue	163,000	83,000	297,000	230,000
Total revenue	31,929,000	28,009,000	92,513,000	81,427,000
Product costs and operating expenses:
Cost of goods sold	10,291,000	9,197,000	30,158,000	26,432,000
Collaboration expenses	93,000	32,000	125,000	41,000
Research and development	3,322,000	3,140,000	9,839,000	10,027,000
Clinical and regulatory	1,196,000	997,000	3,771,000	3,259,000
Sales and marketing	7,327,000	6,706,000	22,406,000	20,462,000
General and administrative	3,692,000	2,362,000	9,282,000	6,871,000
Litigation	0	812,000	0	812,000
Medical device excise taxes	385,000	339,000	1,083,000	995,000
Amortization of purchased technology and intangibles	410,000	404,000	1,234,000	1,162,000
Total product costs and operating expenses	26,716,000	23,989,000	77,898,000	70,061,000
Operating earnings	5,213,000	4,020,000	14,615,000	11,366,000
Other earnings (expenses):
Interest expense	0	(3,000)	0	(9,000)
Foreign exchange gain (loss)	(9,000)	7,000	(8,000)	(2,000)
Earnings before income taxes	5,204,000	4,024,000	14,607,000	11,355,000
Income tax expense	(2,634,000)	(1,352,000)	(6,033,000)	(3,750,000)
Net earnings	$ 2,570,000	$ 2,672,000	$ 8,574,000	$ 7,605,000
Net earnings per share - basic (in dollars per share)	$ 0.15	$ 0.16	$ 0.51	$ 0.47
Net earnings per share - diluted (in dollars per share)	$ 0.15	$ 0.16	$ 0.49	$ 0.45